Whanin signs co-promotion agreement with Lundbeck Korea

Whanin Pharm says it has signed an agreement with Lundbeck Korea to co-promote and distribute nalmefene, an opioid receptor antagonist used primarily in the management of alcohol dependence, in Korea.

H. Lundbeck A/S (Lundbeck) is continuing the development of nalmefene for the treatment of alcohol dependence as scheduled, initiating three phase III clinical trials with the compound.

Nal...